ES2364166B1 - GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. - Google Patents
GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. Download PDFInfo
- Publication number
- ES2364166B1 ES2364166B1 ES200931311A ES200931311A ES2364166B1 ES 2364166 B1 ES2364166 B1 ES 2364166B1 ES 200931311 A ES200931311 A ES 200931311A ES 200931311 A ES200931311 A ES 200931311A ES 2364166 B1 ES2364166 B1 ES 2364166B1
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- response
- predictor
- genomic
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G06F19/20—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Abstract
Huella genómica como predictor de respuesta a tratamiento.#La invención se relaciona con un método de predicción de la respuesta al tratamiento con un taxano más quimioterapia con un antimetabolito, un agente intercalante y un agente alquilante del ADN, en pacientes con cáncer de mama. En concreto, los autores han desarrollado un modelo mediante regresión logística en que el test genómico de 40 genes, combinado con parámetros clínicos, predice con precisión la respuesta patológica completa (RCp) al tratamiento neoadyuvante de paclitaxel más quimioterapia con fluorouracilo, adriamicina y ciclofosfamida (T/FAC) en pacientes de cáncer de mama con una expresión normal del gen HER-2. Dicho modelo tiene mejor rendimiento que las variables clínicas utilizadas rutinariamente.Genomic footprint as a predictor of treatment response. # The invention relates to a method of predicting the response to treatment with a taxane plus chemotherapy with an antimetabolite, an intercalating agent and a DNA alkylating agent, in patients with breast cancer. Specifically, the authors have developed a model through logistic regression in which the genomic test of 40 genes, combined with clinical parameters, accurately predicts the complete pathological response (RCp) to the neoadjuvant treatment of paclitaxel plus chemotherapy with fluorouracil, adriamycin and cyclophosphamide ( T / FAC) in breast cancer patients with a normal expression of the HER-2 gene. This model has better performance than the clinical variables used routinely.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931311A ES2364166B1 (en) | 2009-12-31 | 2009-12-31 | GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. |
PCT/ES2010/070874 WO2011080373A1 (en) | 2009-12-31 | 2010-12-30 | Genomic imprinting used to predict response to a treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931311A ES2364166B1 (en) | 2009-12-31 | 2009-12-31 | GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2364166A1 ES2364166A1 (en) | 2011-08-26 |
ES2364166B1 true ES2364166B1 (en) | 2012-07-10 |
Family
ID=44226196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200931311A Expired - Fee Related ES2364166B1 (en) | 2009-12-31 | 2009-12-31 | GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2364166B1 (en) |
WO (1) | WO2011080373A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013078537A1 (en) * | 2011-11-28 | 2013-06-06 | National Research Council Of Canada | Paclitaxel response markers for cancer |
WO2014080060A1 (en) * | 2012-11-23 | 2014-05-30 | Servicio Andaluz De Salud | Method for predicting the response to chemotherapy treatment in patients with cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2363518A1 (en) * | 2000-11-21 | 2002-05-21 | Affymetrix, Inc. | Methods and computer software products for predicting nucleic acid hybridization affinity |
WO2005008213A2 (en) * | 2003-07-10 | 2005-01-27 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
US20060121511A1 (en) * | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
WO2008060376A2 (en) * | 2006-10-04 | 2008-05-22 | The Johns Hopkins University | Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer |
EP2235211A1 (en) * | 2007-12-28 | 2010-10-06 | Ipsogen | Breast cancer expresion profiling |
-
2009
- 2009-12-31 ES ES200931311A patent/ES2364166B1/en not_active Expired - Fee Related
-
2010
- 2010-12-30 WO PCT/ES2010/070874 patent/WO2011080373A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ES2364166A1 (en) | 2011-08-26 |
WO2011080373A1 (en) | 2011-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017522908A5 (en) | ||
AR055594A1 (en) | PREDICTION OF THE OSEA RECEPTION OF CANCER OF MAMA | |
ES2721424T3 (en) | Bladder Cancer Diagnostic Method | |
UY31816A (en) | AGENT FOR THE TREATMENT AND / OR PREVENTION OF AN AUTOIMMUNE DISEASE AND FOR THE FORMATION OF REGULATORY CELLS | |
ES2422739T3 (en) | Composition for the diagnosis, prevention or treatment of diseases related to cells expressing IL-8 or GRO-, comprising UCB MSC | |
WO2011095623A3 (en) | miRNA IN THE DIAGNOSIS OF OVARIAN CANCER | |
BR112012024718A2 (en) | method for predicting breast cancer recurrence under endocrine treatment | |
WO2010042831A3 (en) | Diagnosis, prognosis and treatment of glioblastoma multiforme | |
PE20120015A1 (en) | METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT | |
JP2015511121A5 (en) | ||
AR061136A1 (en) | PROCESS | |
ES2679373T3 (en) | New RIG-I ligands and methods to produce them | |
BR112012024375A2 (en) | composite layer | |
AR109941A1 (en) | CORN RESISTANT CORN GENERATION OF THE LEAF OF THE NORTH | |
CL2011000894A1 (en) | Process for making a frozen beverage from a frozen confection that has an increased surface area, as well as open / empty spaces | |
WO2010033773A3 (en) | Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways | |
CO2019003583A2 (en) | Efficient data structures for the representation of bioinformatics information | |
WO2018125019A3 (en) | Use of some mirnas for the diagnosis and treatment of diseases associated with insulin | |
WO2013066879A3 (en) | SOLUBLE UROKINASE RECEPTOR (suPAR) IN DIABETIC KIDNEY DISEASE | |
ES2364166B1 (en) | GENOMIC FOOTPRINT AS A PREDICTOR OF TREATMENT RESPONSE. | |
MX2013004747A (en) | Peripheral blood gene markers for early diagnosis of parkinson's disease. | |
SG173635A1 (en) | A method for the systematic evaluation of the prognostic properties of gene pairs for medical conditions, and certain gene pairs identified | |
SG179129A1 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
AR097909A1 (en) | METHOD FOR DETERMINING THE FORECAST OF CANCER CANCER | |
EA201001361A1 (en) | ASSIGNMENT BRICK |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2364166 Country of ref document: ES Kind code of ref document: B1 Effective date: 20120710 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20181011 |